Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease
Alzheimer's disease (AD), a neurodegenerative disorder affects more than 35 million people globally. Acetylcholinesterase suppression is the common approach to enhance the well-being of AD patients by increasing the duration of acetylcholine in the cholinergic synapses. Generally, herbal second...
Saved in:
Main Authors: | , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/145306 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-145306 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1453062023-03-11T20:06:27Z Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease Pitchai, Arjun Rajaretinam, Rajesh Kannan Mani, Rajasekar Nagarajan, Nagasundaram School of Humanities Science::Biological sciences Acetylcholinesterase (AChE) Flavonoids Alzheimer's disease (AD), a neurodegenerative disorder affects more than 35 million people globally. Acetylcholinesterase suppression is the common approach to enhance the well-being of AD patients by increasing the duration of acetylcholine in the cholinergic synapses. Generally, herbal secondary metabolites are reported to be a major resource for acetylcholinesterase inhibitors (AChEIs). Trans-tephrostachin was reported from Tephrosia purpurea for AChE inhibition. Here, we report on the design, synthesis, and assessment of human acetylcholinesterase inhibitory activity from trans-tephrostachin derivatives or analogs as anti-AD agents. The five newly synthesized compounds 4a. 4b, 4c, 4d and 4e displayed potent inhibitory activities with IC50 values of 35.0, 35.6, 10.6, 10.3, and 28.1 μM respectively. AChE enzyme kinetic study was performed for the five derived compounds using the Ellman's method. The Lineweaver-Burk and the secondary plots revealed the mixed inhibition for 4a, 4c and 4d whereas 4b and 4e demonstrated competitive inhibition. Molecular docking and molecular dynamics simulations showed the derivatives or analogs of trans-tephrostachin attained a high binding affinity and efficacy than the standard drug. In conclusion, trans-tephrostachin and its derivative compounds could become effective agents for further drug development to treat AD. Published version 2020-12-17T01:43:03Z 2020-12-17T01:43:03Z 2020 Journal Article Pitchai, A., Rajaretinam, R. K., Mani, R., & Nagarajan, N. (2020). Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease. Heliyon, 6(9), e04930-. doi:10.1016/j.heliyon.2020.e04930 2405-8440 https://hdl.handle.net/10356/145306 10.1016/j.heliyon.2020.e04930 32995619 9 6 en Heliyon © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Science::Biological sciences Acetylcholinesterase (AChE) Flavonoids |
spellingShingle |
Science::Biological sciences Acetylcholinesterase (AChE) Flavonoids Pitchai, Arjun Rajaretinam, Rajesh Kannan Mani, Rajasekar Nagarajan, Nagasundaram Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease |
description |
Alzheimer's disease (AD), a neurodegenerative disorder affects more than 35 million people globally. Acetylcholinesterase suppression is the common approach to enhance the well-being of AD patients by increasing the duration of acetylcholine in the cholinergic synapses. Generally, herbal secondary metabolites are reported to be a major resource for acetylcholinesterase inhibitors (AChEIs). Trans-tephrostachin was reported from Tephrosia purpurea for AChE inhibition. Here, we report on the design, synthesis, and assessment of human acetylcholinesterase inhibitory activity from trans-tephrostachin derivatives or analogs as anti-AD agents. The five newly synthesized compounds 4a. 4b, 4c, 4d and 4e displayed potent inhibitory activities with IC50 values of 35.0, 35.6, 10.6, 10.3, and 28.1 μM respectively. AChE enzyme kinetic study was performed for the five derived compounds using the Ellman's method. The Lineweaver-Burk and the secondary plots revealed the mixed inhibition for 4a, 4c and 4d whereas 4b and 4e demonstrated competitive inhibition. Molecular docking and molecular dynamics simulations showed the derivatives or analogs of trans-tephrostachin attained a high binding affinity and efficacy than the standard drug. In conclusion, trans-tephrostachin and its derivative compounds could become effective agents for further drug development to treat AD. |
author2 |
School of Humanities |
author_facet |
School of Humanities Pitchai, Arjun Rajaretinam, Rajesh Kannan Mani, Rajasekar Nagarajan, Nagasundaram |
format |
Article |
author |
Pitchai, Arjun Rajaretinam, Rajesh Kannan Mani, Rajasekar Nagarajan, Nagasundaram |
author_sort |
Pitchai, Arjun |
title |
Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease |
title_short |
Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease |
title_full |
Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease |
title_fullStr |
Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease |
title_full_unstemmed |
Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease |
title_sort |
molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for alzheimer's disease |
publishDate |
2020 |
url |
https://hdl.handle.net/10356/145306 |
_version_ |
1761781711288401920 |